CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015
 

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015.

More...